## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($323.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Cencora Inc. Stock Slips 4.4%, Underperforms Peers**
- Source: 富途牛牛 | 20251204T170823 | Neutral | Relevance: 100%
-  Cencora Inc. (COR) stock experienced a 4.4% slip, underperforming its peers. This news also briefly mentions Unity Software's financial results, with fourth-quarter revenue increasing 35% year-over-year to $609 million, beating consensus estimates, despite reporting a quarterly loss of 66 cents per share.

**2. Why Cencora (COR) Shares Are Trading Lower Today**
- Source: Finviz | 20251203T152600 | Neutral | Relevance: 99%
- Cencora (COR) shares fell 4.3% after analysts downgraded the stock to a "hold" from a "buy," contributing to a negative trend. Despite this, the stock has shown significant gains year-to-date and over the past five years. The market considered the downgrade meaningful, though it may not fundamentally alter the perception of the business, especially considering the stock's low volatility.

**3. Why Is Cencora (COR) Down 6.3% Since Last Earnings Report?**
- Source: www.sharewise.com | 20251205T182810 | Neutral | Relevance: 99%
-  Cencora (COR) shares have fallen 6.3% since its last earnings report, underperforming the S&P 500, prompting questions about its future stock performance. The company reported strong Q4 fiscal 2025 results, beating earnings and revenue estimates, alongside robust full-year growth and an improved gross margin. Cencora also issued optimistic fiscal 2026 guidance, yet analysts' estimates have shown a downward trend since the earnings release.

**4. JPMorgan Raises Cencora (COR) Price Target After Financial Model Update**
- Source: Insider Monkey | 20251203T145900 | Bullish | Relevance: 99%
- JPMorgan increased its price target for Cencora (NYSE: COR) to $417 from $344 while maintaining an Overweight rating, following an update to the company's financial model. Cencora announced plans to invest $1 billion through 2030 to strengthen its US supply chain and reported Q4 FY25 results that surpassed expectations, with revenue of $83.7 billion. The company also raised its quarterly dividend by 9% to $0.60 per share and projected adjusted operating income growth of 6% to 9% and adjusted EPS growth of 9% to 13%.

**5. Edgestream Partners L.P. Increases Stock Holdings in Cencora, Inc. $COR**
- Source: MarketBeat | 20251205T021505 | Bullish | Relevance: 98%
-  Edgestream Partners L.P. significantly increased its stake in Cencora, Inc. (NYSE:COR) by 1,348.2% in Q2, acquiring an additional 11,392 shares to bring their total holdings to 12,237 shares valued at $3.67 million. This increase comes as analysts have raised price targets and ratings, with Cencora holding a "Moderate Buy" consensus despite recent insider sales and a market downturn. The company also raised its quarterly dividend to $0.60 per share.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |
| 2025-11-11 | JP Morgan | $417 | $344 | +21% |
| 2025-11-11 | Wells Fargo | $405 | $354 | +14% |
| 2025-11-10 | TD Cowen | $400 | $350 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |
| 2025-11-11 | JP Morgan | main | Overweight |
| 2025-11-11 | Wells Fargo | main | Overweight |
| 2025-11-10 | TD Cowen | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +17%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.82 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Analyst sentiment positive (3 raises, avg +17%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $65.4B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.82 |
| Forward P/E | 17.4 |
| Current P/E | 19.2 |
| YoY Growth | 10.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -3.7% to -6.5% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.6pp (needs >3.0% for momentum thesis). Underperforming sector by 4.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.14x) but short-term weakness (below SMA20). MACD histogram bearish (-5.15), momentum weakening. RSI neutral at 40.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.55% (CS: 2) | Weak |
| RSI_14 | 40.3 | Neutral |
| MACD Histogram | -5.15 | Bearish |
| vs SMA20 | 0.943x | Below |
| vs SMA50 | 1.002x | Above |
| vs SMA200 | 1.138x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $339.66
- **Stop Loss:** $323.88 (4.6% risk)
- **Target:** $355.44 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $10,529.46
- **Portfolio %:** 10.53%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*